Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

RX001

Subjects will receive a single RX001 (AAV-hRUNX3) treatment via Intra-tumoral injection

Trial Locations (1)

Konkuk University Medical Center, Seoul

All Listed Sponsors

lead

GeneCraft Inc.

INDUSTRY